Table 3. Clinical settings and follow-up of durvalumab treatment.
| Characteristics | No. respondents [%] |
|---|---|
| Time to durvalumab start | |
| <14 days | 0 [0] |
| 14–28 days | 65 [46] |
| >28 days | 49 [34] |
| Unknown | 29 [20] |
| Imaging used for response evaluation before durvalumab start | |
| CBCT at end of CRT | 8 [6] |
| CT | 125 [87] |
| PET-CT | 7 [5] |
| Others | 3 [2] |
| Unknown | 0 [0] |
| Proportion of patients with toxicity (grade ≥III) during durvalumab treatment | |
| <5% | 31 [22] |
| 5–10% | 100 [70] |
| >10% | 12 [8] |
| Time frame of response evaluation during durvalumab | |
| More frequently than every 3 months | 3 [2] |
| Every 3 months | 120 [84] |
| Less frequently than 3 months | 13 [9] |
| Unknown | 7 [5] |
| Diagnostics used for response evaluation during durvalumab | |
| CT | 124 [87] |
| PET-CT | 14 [10] |
| CT and PET-CT | 2 [1] |
| Unknown | 3 [2] |
CBCT, cone beam computed tomography; CT, computed tomography; PET-CT, positron emission tomography-computed tomography.